



Published in final edited form as:

Radiother Oncol. 2024 January ; 190: 110011. doi:10.1016/j.radonc.2023.110011.

Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses

Elaine LIMKIN¹, Pierre BLANCHARD^{1,2,3}, Benjamin LACAS^{2,4}, Jean BOURHIS^{3,5}, Mahesh PARMAR⁶, Lisa LICITRA⁷, Quynh-Thu LE^{8,9}, Sue YOM⁹, Catherine FORTPIED¹⁰, Johannes LANGENDIJK¹¹, Jan B VERMORKEN¹², Jacques BERNIER¹³, Jens OVERGAARD¹⁴, Jonathan HARRIS⁹, Jean-Pierre PIGNON^{2,3,4}, Anne AUPERIN^{2,3,4} MACH-NC^{*,**} MARCH^{**}

¹Department of Radiation Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Gustave-Roussy, Villejuif, France

²Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Villejuif, France

³Groupe d'Oncologie Radiothérapie Tête Et Cou, Tours, France

⁴Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Gustave-Roussy, Villejuif, France

⁵CHUV, Lausanne, Switzerland

⁶MRC Clinical Trials Unit at UCL, London, United Kingdom

⁷Fondazione IRCCS Istituto Tumori Milan and University of Milan, Italy

⁸Stanford University School of Medicine, Stanford, CA, USA

⁹NRG Oncology, Philadelphia, PA, USA

¹⁰EORTC, Brussels, Belgium

¹¹University Medical Center Groningen, Groningen, Netherlands

Corresponding author: Pierre BLANCHARD, Address: Department of Radiation Oncology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800 Villejuif, FRANCE, pierre.blanchard@gustaveroussy.fr.

*Meta-Analysis of Chemotherapy in Squamous Cell Head and Neck Cancer

**Meta-Analysis of Radiotherapy in Squamous Cell Carcinomas of Head and Neck

The full list of investigators can be found in the supplementary data.

CRedit

Conceptualization : PB, EL, AA, JPP ;

Data curation : AA, BL ;

Formal analysis : AL, BL, JPP ;

Funding acquisition : PB, AA, JPP ;

Investigation : PB, BL, AA ;

Methodology : PB, BL, AA, JPP ;

Resources : PB, BL, JBo, MP, LL, QL, SY, CF, JL, JBB, JBe, JO, JH, JPP, AA ;

Validation : PB, BL, JBo, MP, LL, QL, SY, CF, JL, JBB, JBe, JO, JH, JPP, AA ;

Writing - original draft : EL, PB, AA, JPP ;

Writing - review & editing: PB, EL, BL, JBo, MP, LL, QL, SY, CF, JL, JBB, JBe, JO, JH, JPP, AA

Conflicts of interest: none.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹².Antwerp University Hospital, Edegem, Belgium

¹³.Clinique de Genolier, Genolier, Switzerland

¹⁴.Aarhus University Hospital, Aarhus, Denmark

Keywords

radiation therapy; head and neck cancer; season of treatment

Introduction

Head and neck squamous cell cancer (HNSCC) accounts for approximately 800,000 cases and 400,000 deaths annually worldwide ¹. The standard of care for locally-advanced disease for oral cavity, oropharynx, hypopharynx, and larynx subsites is a multimodality treatment with permutations of radiation therapy (RT), chemotherapy (CT), and surgery, in function of tumor localization. Treatment sequelae in these highly functional zones may significantly affect quality of life; and despite optimal treatment, mortality remains high. The search for factors influencing efficacy and toxicity outcomes continues.

In 2021, Elicin et al published a single institution retrospective study in Switzerland on 655 patients with HNSCC treated with radiotherapy (+/- chemotherapy) between 2002 and 2015 showing that the effect of seasonality of radiotherapy on loco-regional control (5-year LRC, 73% vs. 61%; $p = 0.0108$) and progression-free survival (5-year PFS, 51% vs. 43%; $p = 0.0374$) was superior when radiotherapy was administered during the darker half of the year than during the lighter half ². This period was likewise associated with increased acute toxicity (Toxicity (T), Adverse long-term effects (A), and Mortality risk (M) generated by a treatment program (E=End results) (TAME)) T score 1.98 vs 1.61, $p = 0.0127$) ³. A possible explanation is a variation in cell cycle progression in function of seasons, possibly related to vitamin D levels, with epidemiologic studies showing improved survival for cancers diagnosed during the summer and autumn in Norway ⁴ and in the United Kingdom ⁵. Another possibility seen in preclinical studies is that the disruption of the circadian rhythm leads to accelerated tumor growth ^{6,7}. However, the retrospective single center nature of the reported studies are at risk of false positivity.

The aim of this paper is to investigate the impact of the season of radiotherapy delivery in outcomes of HNSCC treated with radiotherapy in two large, multi-institutional prospective datasets of randomized trials. Individual patient data from two previously published meta-analyses, the concomitant part of the Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) ^{8,9} and the Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and neck (MARCH) ^{10,11}, were used.

Materials and Methods

Patients and trials

Inclusion criteria for each subset was previously described^{8,9,11,12} and detailed in the Supplementary data. Briefly, patients with non-metastatic oral cavity, oropharynx,

hypopharynx, or larynx HNSCC undergoing first-line curative treatment with available duration of RT were included. The data initially collated consisted of age, sex, tumor site, T and N classification, stage, histology, performance status, allocated treatment, date of randomization, and dose and duration of radiotherapy. The date and site of the first recurrence and second primary were recorded, as well as survival status and date of last follow-up. Patients with missing data on sex, tumor site, stage or season of treatment were excluded from the analyses. All trials of the MARCH dataset were eligible and in the MACH-NC dataset, only trials that studied chemotherapy concomitant to radiotherapy and randomized patients since 1994 were eligible. Details on the trials included are in Supplementary Tables S1 and S2. MACH-NC and MARCH steering committees approved the proposed research question, and a protocol for statistical analysis was written prior to analysis. The work has been carried out in accordance with the Declaration of Helsinki.

Definition of season

Dark season was defined, similar to the definition of by Elicin et al ², as mid-radiotherapy date between September 22nd, year X and March 20th, year X+1 for studies performed in the Northern hemisphere. Light season was defined as a mid-radiotherapy date between March 20th, year X and September 22nd, year X. For the trials performed in the Southern hemisphere, RIO ¹³ and TROG ¹⁴, these Dark/Light definitions were inverted. As radiotherapy dates were often not available, mid-radiotherapy date was estimated for each patient using the date of randomization and the radiotherapy duration. When radiotherapy duration was not available, the theoretical duration planned in the trial protocol was used.

Outcomes

Progression-free survival was the primary endpoint. Progression-free survival was defined as the time between randomization and progression, death from any cause or last follow-up, whichever occurred first. Locoregional failure (LRF) was the secondary endpoint defined as locoregional failure alone or associated with metastatic failure as first event. If distant failure alone or death without failure occurred before LRF, patient was censored at the date of these events. Patients alive without failure were censored at the date of last follow-up.

Statistical analysis

The impact of dark/light season of radiotherapy on outcomes was estimated with a Cox proportional hazards model stratified by trial for univariate analysis and then adjusted on sex (male, female), tumor site (oral cavity, oropharynx, larynx, hypopharynx, other), stage (I-II, III-V), treatment (control arm, experimental arm) for multivariable analysis. Hazard ratios (HR) and their 95% confidence intervals (CI) were estimated. Factors for adjustment in Cox models were similar to those used by Elicin et al, except the time of the day for radiotherapy delivery (morning/afternoon) which was not available in the MARCH and MACH-NC datasets, and the treatment arm was added. Chi-square heterogeneity test was used to test for statistical heterogeneity of season effect among trials. We also calculated the I^2 statistic expressing the proportion of variability in the season effect attributable to heterogeneity rather than to the sampling error, with an I^2 value below 30% considered indicative of low heterogeneity¹⁵.

Several sensitivity analyses were performed. As radiotherapy dates were often not available, there was some uncertainty as to the attribution of the light or dark season in patients treated around the equinoxes. Thus, we performed a sensitivity analysis restricted to patients treated around the solstices (May, June and July versus November, December and January). Another sensitivity analysis was based on patients who received “complete radiotherapy” defined as at least 90% of the planned radiotherapy dose in MARCH or at least 60 Gy in MACH-NC, in less than 10 weeks. Patients with a missing dose or a missing duration were excluded from this analysis. Finally, in the MACH-NC dataset, an analysis based only on patients of the experimental arms (RT+ concomitant CT) and in the MARCH dataset, an analysis based only on trials performed in Northern countries (Northern Europe and Canada), where differences in daytime between dark and light seasons are more pronounced, were performed.

Five-year PFS and LRF rates were estimated using Kaplan-Meier method. All P values are two-sided. Analyses were done with the SAS 9.4 software.

Results

There were 11 320 patients from 33 trials of MARCH and 6 276 patients from 29 trials of MACH-NC included in the analysis (Figure 1). Patient characteristics are summarized in Table 1. Median age was 59 years old (interquartile range (IQR) 52; 66) and 56 (IQR 49; 63) for MARCH and MACH-NC datasets, respectively. For the two datasets, more than 80% of patients were male, and the predominant tumor site was oropharynx followed by larynx. Tumors were mainly AJCC Stage IV, and the median RT dose was 68 Gy (IQR 64; 70) for MARCH and 66 Gy (IQR 60; 70) for MACH-NC with a median duration of 43 (IQR 36; 48) and 47 (IQR 40; 52) days, respectively. In each dataset, the patient, tumor and radiotherapy characteristics were similar between patients treated during the dark and the light season (Table S3).

The median follow-up was 7.8 years (IQR 5.3–11.7) in the MARCH dataset and 8.2 years (IQR 4.9–11.5) in the MACH-NC dataset.

In terms of progression-free survival, there was no evidence of a benefit on PFS of the dark season for radiotherapy delivery in the MARCH dataset (HR: 1.01 [95%CI 0.97; 1.05], $p=0.72$) or in the MACH-NC dataset (HR: 1.00 [95%CI 0.94; 1.06], $p=1.00$) (Table 2). In the MARCH dataset, the 5-year PFS rates were 35.6% (95%CI 34.4%; 36.9%) for patients treated during the light season and 35.5% (95%CI 34.2%; 36.8%) for patients treated during the dark season. In the MACH-NC dataset, the 5-year PFS rates were 26.3% (95%CI 24.7%; 27.9%) and 27.4% (95%CI 25.7%; 29.1%) in the light and dark seasons respectively. In multivariable analysis in both datasets, patient sex, tumor site and tumor stage were strong prognostic factors for PFS.

When the analysis was restricted to patients treated around the solstices, the HR of PFS events were still around 1 in the MARCH dataset (1.03 [95%CI 0.97; 1.09]) and in the MACH-NC dataset (1.05 [95%CI 0.97; 1.14]) (Table 3).

Due to the lack of data on dose or duration of radiotherapy, we could not assess whether radiotherapy was “complete” for 607 patients of the MARCH dataset and 1 670 of the MACH-NC dataset. Of the remaining patients, 516 of the MARCH dataset and 1 171 of the MACH-NC dataset did not receive “complete” radiotherapy. Thus, the sensitivity analysis in patients treated with “complete” radiotherapy were based on 10 197 patients from MARCH and 3 435 patients from MACH-NC. They showed no effect of the dark season on PFS, HR 1.00 (95%CI 0.95; 1.04, p=0.93) in MARCH and HR 0.99 (95%CI 0.92; 1.07, p=0.87) in MACH-NC. The results were similar when the analysis was restricted to patients treated around the solstices (Table 3).

In the MARCH dataset, when the analysis was limited to the five trials performed in Northern countries treated with “complete” radiotherapy (2 615 patients from ARTSCAN¹⁶ (Sweden), DAHANCA 6&7¹⁷ and DAHANCA 9¹⁸ (Denmark), PMH Toronto¹⁹ (Canada), BCCA 9113²⁰ (Canada)), no significant effect of season on PFS was observed, with a HR of 0.93 (95%CI 0.85; 1.02, p=0.11) for the dark season in Cox model stratified by trial and adjusted on sex, tumor site, stage and treatment. The HR was closer to 1 when the analysis was restricted to patients treated around the solstices (0.99 [95%CI 0.87; 1.12]) (Table 3).

In the MACH-NC dataset, when the analysis was limited to the patients of the experimental arm (concomitant chemo-radiotherapy) treated with “complete” radiotherapy (1 703 patients), no significant effect of season on PFS was observed, with a HR of 0.96 (95%CI 0.86; 1.08, p=0.52) for the dark season in Cox model stratified by trial and adjusted on sex, tumor site and stage. The result was similar when the analysis was restricted to patients treated around the solstices (Table 3).

Data on locoregional failure was available for 11 257 patients of the MARCH dataset and 5 146 patients of the MACH-NC dataset. There was no evidence of a decrease in LRF when patients were treated during the dark season as compared to the light season in the MARCH dataset (HR: 1.00 [95%CI 0.94; 1.06, p=0.95) or in the MACH-NC dataset (HR: 0.99 [95%CI 0.91; 1.07], p=0.77) (Table 4). In the MARCH dataset, the 5-year LRF rates were 43.1% (95%CI 41.7%; 44.5%) for patients treated during the light season and 43.1% (95%CI 41.7%; 44.6%) for patients treated during the dark season. In the MACH-NC dataset, the 5-year LRF incidence rates were 55.1% (95%CI 53.0%; 57.2%) and 54.0% (95%CI 51.7%; 56.3%) in the light and dark seasons respectively.

When the analysis was restricted to patients treated around the solstices, the HR of LRF were still around 1 in the MARCH dataset (1.02 [95%CI 0.94; 1.11]) and in the MACH-NC dataset (1.03 [95%CI 0.92; 1.16]) (Table 5).

The sensitivity analyses in patients treated with “complete” radiotherapy were based on 10 163 patients from MARCH and 2 963 patients from MACH-NC (Table 5). They showed no effect of the dark season on LRF, HR 1.00 (95%CI 0.94; 1.06, p=0.95) in MARCH and HR 0.98 (95%CI 0.88; 1.09, p=0.67) in MACH-NC. The results were similar when the analysis was restricted to patients treated around the solstices.

In the MARCH dataset, when the analysis was limited to the five trials performed in Northern countries (2 611 patients) treated by “complete” RT, no significant effect of season

on LRF was observed, with a HR of 0.92 (95%CI 0.81; 1.04, $p=0.19$) for the dark season in Cox model stratified by trial and adjusted on sex, tumor site, stage and treatment. The HR was closer to 1 when the analysis was restricted to patients treated around the solstices (1.01 [95%CI 0.85; 1.21]).

In the MACH-NC dataset, when the analysis was limited to the patients of the experimental arm (concomitant chemo-radiotherapy) treated by “complete” radiotherapy (1477 patients), no significant effect of season on LRF was observed, with a HR of 0.91 (95%CI 0.78; 1.07, $p=0.27$) for the dark season in Cox model stratified by trial and adjusted on sex, tumor site and stage. The result was similar when the analysis was restricted to patients treated around the solstices.

Discussion

In this large multicentric analysis of individual patient data, no effect of season was seen in the outcomes of patients treated with radiation therapy for head and neck cancer. This is in contrast with the findings of Elicin et al, who found that treatment during the “dark” season (between September 22nd to March 20th of the following year) was associated with better tumor control and better PFS. Our results are not surprising, as there are no strong pathophysiologic or radiobiological rationale for their findings. One of the principal hypotheses is that the season of diagnosis and/or treatment affects outcomes through variation in vitamin D levels, which varies with sunlight exposure. The plausibility of this phenomenon remains unclear. In an epidemiological study in the United Kingdom on breast, colorectal, lung, and prostate primaries, when season of diagnosis and cumulative sunlight hours were mutually adjusted, the effect of season persisted but the sunlight effect did not⁵. Furthermore, patients diagnosed in summer and autumn showed increased survival compared with those diagnosed in the winter, which is in contrast with the results of Elicin et al.

The effect of vitamin D was studied in HNSCC, where pre-treatment serum 25-hydroxyvitamin D and total vitamin D intake were measured for stage I and II patients undergoing RT. In multivariable analysis, no association was observed with recurrence ($p=0.99$), incidence of second primaries ($p=0.64$), or overall mortality ($p=0.53$)²¹. In contrast, a recently published systematic review with meta-analysis of case-control and cohort studies evaluating vitamin D levels and head and neck cancer (HNC) had mortality as a secondary outcome, and reported increased HNC survival in two studies (pooled HR 1.13, 95%CI 1.05; 1.22) and decreased HNC mortality in three studies (pooled HR 0.75, 95%CI 0.60 to 0.94) with high concentrations of circulating 25-hydroxyvitamin D²². These results should probably be interpreted with caution, as they are based on observational studies.

The impact of seasons and exposure to sunlight would probably be more marked in patients living closer to polar regions than closer to the equator, as seasonal differences are more pronounced. We tested this hypothesis with planned analysis on the Northern trials (Denmark, Sweden, Canada) in the MARCH subset (2 615 patients), but again did not find significant difference on PFS (HR 0.93 [95%CI 0.85; 1.02], $p=0.11$) or LRC (HR 0.92

[95%CI 0.81; 1.04], $p=0.19$), reiterating the lack of impact of season on treatment effect in HNSCC.

Another hypothesis is that tumor control and toxicities vary with the time of radiation therapy, possibly in relation to the variations in the circadian clock of the cell cycle. For example, the G2-M phase, considered the most radiosensitive of the cell cycle, was shown to occur in the late afternoon and evening in human oral mucosa, as measured by increased secretion of cell-cycle-associated proteins cyclin A and B1²³. The clinical implication of these findings was studied in two prospective trials evaluating mucositis as the primary endpoint for patients receiving RT for HNSCC. No statistically significant differences were seen between morning and evening treatments, 38% vs. 26% ($p = 0.08$) in the Indian cohort and 52.9% vs. 62.4% ($p=0.17$) in the Canadian cohort.^{24,25} Likewise, Elicin et al did not find an effect of treatment time on tumor control or on toxicity, and this was not tested in our current study because data were not available.

The main limitation of this study is its retrospective nature, with data on treatment time and treatment duration not specifically collected as they were not of interest in the original meta-analyses. Nevertheless, mid-treatment time and corresponding season was available for the majority of the subjects, and one of the strengths of this study is the availability of data from a large number of countries, in particular Northern countries where differences were expected to be more pronounced. Furthermore, the season of diagnosis or treatment inherently cannot be randomized in prospective trials, and the utilization of these two large multi-institutional databases likely eliminated selection bias. Even if effects have been found in preclinical studies, these are likely not translated in the clinical setting. Significant prognostic factors found in this study are consistent with current knowledge: sex, tumor site, and tumor stage^{26–28}.

Conclusion

The season of radiotherapy delivery was not seen to impact PFS or loco-regional failure in two large databases of non-metastatic HNSCC. We could not confirm the findings from the single center retrospective study of Elicin et al, which is possibly a false positive result.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the trialists and the collaborative groups for their contributions and for sharing their data.

Funding:

the meta-analysis team and its projects were supported by a grant from the French national cancer institute (PHRC-K15-189) and by the GORTEC group. NRG Oncology data collection was supported by U10CA180868 (NRG Oncology Operations) and U10CA180822 (NRG Oncology SDMC).

References

1. Sung H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* 71, 209–249 (2021). [PubMed: 33538338]
2. Elicin O. et al. The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer. *Radiother. Oncol.* 158, 293–299 (2021). [PubMed: 33848563]
3. Brolese EK et al. The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden. *Radiother. Oncol.* 158, 162–166 (2021). [PubMed: 33667582]
4. Robsahm TE, Tretli S, Dahlback A. & Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). *Cancer Causes Control* 15, 149–158 (2004). [PubMed: 15017127]
5. Lim H-S et al. Cancer survival is dependent on season of diagnosis and sunlight exposure. *Int. J. Cancer* 119, 1530–1536 (2006). [PubMed: 16671100]
6. Van Dycke KCG et al. Chronically Alternating Light Cycles Increase Breast Cancer Risk in Mice. *Curr. Biol.* 25, 1932–1937 (2015). [PubMed: 26196479]
7. Papagiannakopoulos T. et al. Circadian Rhythm Disruption Promotes Lung Tumorigenesis. *Cell Metab.* 24, 324–331 (2016). [PubMed: 27476975]
8. Pignon JP, Bourhis J, Domenge C. & Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. *Lancet* 355, 949–955 (2000). [PubMed: 10768432]
9. Lacas B. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. *Radiother. Oncol.* 156, 281–293 (2021). [PubMed: 33515668]
10. Bourhis J. et al. Conventional vs modified fractionated radiotherapy. meta-analysis of radiotherapy in head & neck squamous cell carcinoma : a meta-analysis based on individual patient data. *Int. J. Radiat. Oncol. Biol. Phys.* 54, 71–72 (2002).
11. Lacas B. et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncol.* 18, 1221–1237 (2017). [PubMed: 28757375]
12. Bourhis J. et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet* 368, 843–854 (2006). [PubMed: 16950362]
13. Pinto LH, Canary PC, Araújo CM, Bacelar SC & Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 21, 557–562 (1991). [PubMed: 1869454]
14. Poulsen MG et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. *Radiother. Oncol.* 60, 113–122 (2001). [PubMed: 11439206]
15. Higgins JPT & Thompson SG Quantifying heterogeneity in a meta-analysis. *Stat. Med.* 21, 1539–1558 (2002). [PubMed: 12111919]
16. Zackrisson B. et al. Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma – The ARTSCAN study. *Radiotherapy and Oncology* vol. 100 41–48 Preprint at 10.1016/j.radonc.2010.12.010 (2011). [PubMed: 21295880]
17. Overgaard J. et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. *Lancet* 362, 933–940 (2003). [PubMed: 14511925]
18. Evensen JF et al. DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). *Acta Oncologica* vol. 58 1502–1505 Preprint at 10.1080/0284186x.2019.1629012 (2019). [PubMed: 31282236]
19. Cummings B. et al. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. *Radiother. Oncol.* 85, 7–16 (2007). [PubMed: 17920715]

20. Jackson SM, Weir LM, Hay JH, Tsang J. & Durham JS A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. *Cancer/Radiothérapie* vol. 2 84–85 Preprint at 10.1016/s1278-3218(98)89072-0 (1998).
21. Meyer F. et al. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. *International Journal of Cancer* vol. 128 1741–1746 Preprint at 10.1002/ijc.25496 (2011). [PubMed: 20533282]
22. Pu Y. et al. Association Between Vitamin D Exposure and Head and Neck Cancer: A Systematic Review With Meta-Analysis. *Front. Immunol.* 12, 627226 (2021).
23. Bjarnason GA, Jordan RC & Sothorn RB Circadian variation in the expression of cell-cycle proteins in human oral epithelium. *Am. J. Pathol.* 154, 613–622 (1999). [PubMed: 10027418]
24. Goyal M. et al. Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. *Int. J. Radiat. Biol.* 85, 504–509 (2009). [PubMed: 19412843]
25. Bjarnason GA et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). *Int. J. Radiat. Oncol. Biol. Phys.* 73, 166–172 (2009). [PubMed: 18805649]
26. Cadoni G. et al. Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy. *Acta Otorhinolaryngol. Ital.* 37, 458–466 (2017). [PubMed: 28663597]
27. Mehanna H, West CML, Nutting C. & Paleri V. Head and neck cancer—Part 2: Treatment and prognostic factors. *BMJ* 341, (2010).
28. Blanchard P. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. *Radiother. Oncol.* 100, 33–40 (2011). [PubMed: 21684027]

Highlights

- The season of radiotherapy delivery (fall/winter versus spring/summer) was queried.
- Season of treatment does not influence either PFS or LRF in head and neck cancer.
- No impact was seen even in Northern countries where differences are expected to be greater.




Fig. 1.
Patient inclusion flowchart.

Table 1:

Patients' characteristics

	MARCH		MACH-NC	
	N=11 320	%	N=6 276	%
Age (years)				
Median	59 ^a		56 ^d	
(Interquartile range)	(52–66)		(49–63)	
Sex				
Male	9400	83.0	5299	84.4
Female	1920	17.0	977	15.6
Primary site				
Oral cavity	1495	13.2	1025	16.3
Oropharynx	4679	41.2	2746	43.8
Larynx	3870	34.2	1294	20.6
Hypopharynx	1123	9.9	965	15.4
Other	153	1.4	246	3.9
T-stage				
T0	4	<0.1	17	0.3
T1	1410	12.5	271	4.3
T2	3457	30.5	1140	18.2
T3	3564	31.5	2321	37.0
T4	2874	25.4	2511	40.0
Unknown	11	0.1	16	0.3
N-stage				
N0	5270	46.6	1678	26.7
N1	1917	16.9	951	15.2
N2	3329	29.4	2584	41.2
N3	801	7.1	593	9.4
N+			465	7.4
Unknown	3	<0.1	5	0.1
Stage				
I	1029	9.1	13	0.2
II	1849	16.3	296	4.7
III	2946	26.0	1605	25.6
IV	5496	48.6	4362	69.5
Treatment arm				
Control	5266	46.5	3154	50.3
Experimental	6054	53.5	3122	49.7
Dose of radiotherapy (Gy)				
Median	68 ^b		66 ^e	
(Interquartile range)	(64–70)		(60–70)	

	MARCH		MACH-NC	
	N=11 320	%	N=6 276	%
Radiotherapy duration (days)				
Median	43 ^c		47 ^f	
(Interquartile range)	(36–48)		(40–52)	
Season of radiotherapy				
Light	5815	51.4	3386	54.0
Dark	5505	48.6	2890	46.0

^aMissing for 1 patient

^bMissing for 594 patients

^cMissing for 615 patients

^dMissing for 4 patients

^eMissing for 1614 patients

^fMissing for 1581 patients

Table 2:

Effect of dark/light season of radiotherapy delivery on progression-free survival in all patients

MARCH n=11 320 patients				MACH-NC n=6 276 patients		
	No. events / No. patients	HR [95% CI]	p-value	No. events / No. patients	HR [95% CI]	p-value
Univariate						
Season of RT*			0.68			0.96
Light	4210 / 5815	Reference		2623 / 3386	Reference	
Dark	3984 / 5505	1.01 [0.97 ; 1.05]		2251 / 2890	1.00 [0.95 ; 1.06]	
Multivariable						
Season of RT			0.72			1.00
Light	4210 / 5815	Reference		2623 / 3386	Reference	
Dark	3984 / 5505	1.01 [0.97 ; 1.05]		2251 / 2890	1.00 [0.94 ; 1.06]	
Sex			< 0.0001			0.001 0
Male	6831 / 9400	Reference		4133 / 5299	Reference	
Female	1363 / 1920	0.87 [0.82 ; 0.92]		741 / 977	0.87 [0.81 ; 0.95]	
Tumor site			< 0.0001			< 0.0001
Oral Cavity	1191 / 1495	Reference		836 / 1025	Reference	
Oropharynx	3455 / 4679	0.65 [0.60 ; 0.70]		2101 / 2746	0.68 [0.62 ; 0.75]	
Larynx	2472 / 3870	0.67 [0.62 ; 0.72]		959 / 1294	0.61 [0.55 ; 0.68]	
Hypopharynx	962 / 1123	1.01 [0.92 ; 1.10]		796 / 965	0.83 [0.75 ; 0.92]	
Other	114 / 153	0.61 [0.50 ; 0.75]		182 / 246	0.65 [0.55 ; 0.77]	
Stage			< 0.0001			< 0.0001
I-II	1650 / 2878	0.55 [0.51 ; 0.59]		194 / 309	0.56 [0.48 ; 0.66]	
III-IV	6544 / 8442	Reference		4680 / 5967	Reference	
Treatment arm			< 0.0001			< 0.0001
Control	3831 / 5266	Reference		2531 / 3154	Reference	
Experimental	4363 / 6054	0.89 [0.85 ; 0.93]		2343 / 3122	0.80 [0.75 ; 0.84]	

HR: Hazard Ratio, CI: Confidence Interval

* There was no heterogeneity between trials for the estimation of season effect: MARCH $I^2=0\%$, $p=0.63$; MACH-NC $I^2=0\%$, $p=0.95$.

Table 3:

Sensitivity analyses - effect of dark/light season of radiotherapy delivery on progression-free survival (HR estimated in Cox model stratified by study and adjusted for sex, tumor site, stage and treatment arm)

MARCH				MACH-NC		
	No. events / No. patients	HR [95% CI]	p-value	No. events / No. patients	HR [95% CI]	p-value
Only when radiotherapy done around solstices				Only when radiotherapy done around solstices		
Season of RT	n=5684 patients		0.38	n=3156 patients		0.21
Light	2139 / 2946	Reference		1328 / 1716	Reference	
Dark	1982 / 2738	1.03 [0.97 ; 1.09]		1142 / 1440	1.05 [0.97 ; 1.14]	
Complete RT				Complete RT		
Season of RT	n=10197 patients		0.93	n=3435 patients		0.87
Light	3783 / 5268	Reference		1449 / 1867	Reference	
Dark	3524 / 4929	1.00 [0.95 ; 1.04]		1220 / 1568	0.99 [0.92 ; 1.07]	
Complete RT and only around solstices				Complete RT and only around solstices		
Season of RT	n=5127 patients		0.63	n=1718 patients		0.87
Light	1933 / 2685	Reference		728 / 930	Reference	
Dark	1745 / 2442	1.02 [0.95 ; 1.08]		623 / 788	0.99 [0.89 ; 1.11]	
Northern trials and complete RT				Concomitant RT-CT arm and complete RT*		
Season of RT	n=2615 patients		0.11	n=1703 patients		0.52
Light	984 / 1297	Reference		692 / 932	Reference	
Dark	980 / 1318	0.93 [0.85 ; 1.02]		577 / 771	0.96 [0.86 ; 1.08]	
Northern trials, complete RT, only around solstices				Concomitant RT-CT arm, complete RT, only around solstices*		
Season of RT	n=1341 patients		0.86	n=832 patients		0.65
Light	514 / 681	Reference		347 / 456	Reference	
Dark	489 / 660	0.99 [0.87 ; 1.12]		287 / 376	0.96 [0.82 ; 1.13]	

HR: Hazard Ratio, CI: Confidence Interval

* HR estimated in Cox model stratified by study and adjusted for sex, tumor site and stage.

Table 4:

Effect of dark/light season of radiotherapy delivery on loco-regional failure in all patients

MARCH n=11 257 patients				MACH-NC n=5 146 patients		
	No. events / No. patients	HR [95% CI]	p-value	No. events / No. patients	HR [95% CI]	p-value
Univariate						
Season of RT*			0.89			0.95
Light	2290 / 5786	Reference		1342 / 2798	Reference	
Dark	2143 / 5471	1.00 [0.94 ; 1.06]		1113 / 2348	1.00 [0.92 ; 1.08]	
Multivariable						
Season of RT			0.95			0.77
Light	2290 / 5786	Reference		1342 / 2798	Reference	
Dark	2143 / 5471	1.00 [0.94 ; 1.06]		1113 / 2348	0.99 [0.91 ; 1.07]	
Sex			0.004			0.07
Male	3698 / 9347	Reference		2092 / 4388	Reference	
Female	735 / 1910	0.89 [0.82 ; 0.96]		363 / 758	0.90 [0.81 ; 1.01]	
Tumor site			< 0.0001			< 0.0001
Oral Cavity	790 / 1487	Reference		507 / 827	Reference	
Oropharynx	1908 / 4659	0.55 [0.50 ; 0.60]		1079 / 2336	0.65 [0.58 ; 0.73]	
Larynx	1153 / 3851	0.49 [0.45 ; 0.55]		394 / 983	0.53 [0.45 ; 0.63]	
Hypopharynx	516 / 1109	0.73 [0.65 ; 0.81]		391 / 834	0.74 [0.65 ; 0.86]	
Other	66 / 151	0.52 [0.40 ; 0.67]		84 / 166	0.82 [0.64 ; 1.06]	
Stage			<0.0001			0.0021
I-II	771 / 2869	0.49 [0.45 ; 0.55]		22 / 91	0.51 [0.33 ; 0.78]	
III-IV	3662 / 8388	Reference		2433 / 5055	Reference	
Treatment arm			<0.0001			<0.0001
Control	2223 / 5249	Reference		1349 / 2549	Reference	
Experimental	2210 / 6008	0.82 [0.77 ; 0.87]		1106 / 2597	0.68 [0.63 ; 0.73]	

HR: Hazard Ratio, CI: Confidence Interval

* There was no heterogeneity between trials for the estimation of season effect: MARCH $I^2=0\%$, $p=0.85$; MACH-NC $I^2=14\%$, $p=0.25$.

Table 5:

Sensitivity analyses - effect of dark/light season of radiotherapy delivery on loco-regional failure (HR estimated in Cox model stratified by study and adjusted for sex, tumor site, stage and treatment arm)

MARCH				MACH-NC		
	No. events / No. patients	HR [95% CI]	P-value	No. events / No. patients	HR [95% CI]	p-value
Only when radiotherapy done around solstices				Only when radiotherapy done around solstices		
Season of RT	n=5654 patients		0.60	n=2583 patients		0.57
Light	1151 / 2933	Reference		704 / 1436	Reference	
Dark	1053 / 2721	1.02 [0.94 ; 1.11]		541 / 1147	1.03 [0.92 ; 1.16]	
Complete RT				Complete RT		
Season of RT	n=10163 patients		0.95	n=2963 patients		0.67
Light	2015 / 5251	Reference		780 / 1614	Reference	
Dark	1877 / 4912	1.00 [0.94 ; 1.06]		637 / 1349	0.98 [0.88 ; 1.09]	
Complete RT and only around solstices				Complete RT and only around solstices		
Season of RT	n=5109 patients		0.52	n=1497 patients		1.00
Light	1664 / 2678	Reference		400 / 826	Reference	
Dark	1504 / 2431	1.03 [0.94 ; 1.13]		317 / 671	1.00 [0.86 ; 1.16]	
Northern trials and complete RT				Concomitant RT-CT arm and complete RT[*]		
Season of RT	n=2611 patients		0.19	n=1477 patients		0.27
Light	485 / 1296	Reference		344 / 809	Reference	
Dark	475 / 1315	0.92 [0.81 ; 1.04]		268 / 668	0.91 [0.78 ; 1.07]	
Northern trials, complete RT, only around solstices				Concomitant RT-CT arm, complete RT, only around solstices[*]		
Season of RT	n=1338 patients		0.87	n=727 patients		0.42
Light	244 / 680	Reference		180 / 404	Reference	
Dark	242 / 658	1.01 [0.85 ; 1.21]		124 / 323	0.91 [0.72 ; 1.15]	

HR: Hazard Ratio, CI: Confidence Interval

^{*} HR estimated in Cox model stratified by study and adjusted for sex, tumor site and stage.